Your body repairs and regenerates during rest, making this the optimal time for these nutrients to work
Brand-Name Medication Costs: Annual Cost Comparison (Without Insurance): With Insurance (Variable): If Covered with Low Copay ($25-$50/month): GLP-1s become most cost-effective options Worth pursuing insurance approval if possible But many plans dont cover or have high deductibles Typical Insurance Scenario: Copay: $200-$300/month Annual cost: $2,400-$3,600 Still less than full price but not cheap Many Patients Find: Insurance approval difficult Prior authorization denied Cheaper to pay cash for compounded options Compounded Medication Costs: Annual Cost Comparison: Savings Analysis: Switching from Brand to Compounded: Wegovy Compounded Semaglutide (TrimRx): Monthly savings: $1,150 Annual savings: $13,800 Same effectiveness (both semaglutide) Zepbound Compounded Tirzepatide (TrimRx): Monthly savings: $720 Annual savings: $8,640 Same effectiveness (both tirzepatide) Total Cost Over 18-Month Treatment: To Lose 50 Pounds: To reach 50-pound goal: Compounded tirzepatide: $6,282 total (18 months) Compounded semaglutide: $4,776 total (24 months to reach 50 lbs) Savings vs brand: $13,000-$19,000 Cost Per Pound Lost: Most Cost-Effective Options: Compounded Semaglutide: $97/pound Compounded Tirzepatide: $112/pound Phentermine-Topiramate: $176/pound Brand Tirzepatide: $344/pound Brand Semaglutide: $656/pound Least Cost-Effective: Saxenda: $840/pound Contrave: $300/pound Orlistat: $180/pound (but only 10 pounds total) Hidden Costs: Additional Expenses to Consider: Medical Visits: In-person visits: $150-$300 each Multiple visits for prescription and monitoring Telehealth typically includes visits in monthly cost Lab Work: Initial labs: $150-$300 Periodic monitoring: $100-$200 May be required by some providers Anti-Nausea Medication: If needed for side effects: $10-$30/month Not everyone requires Supplies: Sharps containers: $5-10 Alcohol swabs: $5-10 Usually included with compounded medications Transportation: Gas, parking for in-person appointments Time off work Eliminated with telehealth Insurance Premiums: If paying for insurance primarily for medication coverage Consider if compounded cash-pay might be cheaper overall Value Beyond Weight Loss: Health Improvements: GLP-1 medications provide benefits beyond weight: Reduced diabetes risk: 60-70% reduction Better blood pressure: Average 5-10 mmHg reduction Improved cholesterol: 10-20% improvement in lipids Cardiovascular benefits: 20% reduction in major events (semaglutide proven) Better quality of life: Significant improvements in surveys Reduced joint pain: From weight reduction Better sleep: Improvement in sleep apnea When calculating value, include: Prevented medical costs from obesity complications Improved productivity and quality of life Reduced need for other medications Delayed or prevented need for bariatric surgery Long-Term Cost Considerations: Maintenance Phase: Most patients need ongoing treatment: May reduce to lower maintenance dose Continue indefinitely to prevent regain Long-term cost becomes important factor Budget for: 18-24 months active weight loss phase Indefinite maintenance phase Choose sustainable cost option Return on Investment: Healthcare Cost Savings: Obesity-related annual medical costs: $1,400-$2,700/year more than normal weight Type 2 diabetes: Additional $9,600/year Cardiovascular disease: Additional $18,000/year Weight loss medication costing $2,400-$4,200/year can prevent $10,000-$20,000/year in obesity-related medical expenses
Ozempic and Rybelsus are both approved by the US Food and Drug Administration (FDA) to treat adults with type 2 diabetes by controlling blood sugar levels
Additionally, both semaglutide and tirzepatide showed promise in improving metabolic dysfunction-associated steatotic liver disease (MASLD), mitigating systemic inflammation, and contributing to improvements in liver-related outcomes, including steatosis resolution and fibrosis-related endpoints, in clinical trials
This timeframe generally corresponds with the body's adaptation period to the medication and its metabolic effects
10.1016/j.neuropharm.2019.02.020 74 VestlundJ.BergquistF.LicheriV.AdermarkL.JerlhagE
